The value of osteoporosis interventions: evaluating the cost-effectiveness and incorporating patients’ preference

骨质疏松症（OP）造成严重的疾病和经济负担。在澳大利亚，许多药物是公开提供和补贴的，许多新的药物即将问世。然而，如果没有坚实的卫生经济证据，这些措施的性价比值得怀疑。此外，患者对OP治疗的偏好尚不清楚。我的项目是开发一个全球卫生经济学模型，以确定具有成本效益的治疗方法，并引起患者对不同OP治疗的偏好。

Osteoporosis (OP) poses substantial disease and economic burden. Many medications are publicly available and subsidized in Australia, and many new medications are on the horizon. Their value for money, however, is questionable without solid health economic evidence. In addition, patient preference for OP treatment is not well understood. My project is to develop a global health economics model to identify cost-effective treatments, and to elicit patient preference for different OP treatments.